Loading organizations...
Loading organizations...
JH Cispoly: Biotechnology company developing molecular diagnostic technology for early detection of ovarian, cervical, and endometrial cancers.
JH Cispoly, based in Jiangsu province, China, develops diagnostic technology and equipment for the early detection of gynecological tumors, including ovarian, cervical, and endometrial cancers, with a focus on enabling timely diagnosis and improved patient outcomes. The organization's comprehensive solutions encompass molecular diagnostic kits, reagents, and related R&D, manufacturing, distribution, registration, and service support within the women's health and biotechnology sectors. JH Cispoly has secured significant investment, completing a Series B financing round of hundreds of millions of yuan, led by ZhenFund. This substantial funding follows an earlier Seed Round in 2021 and further Series B participation in 2023 from Sunland Fund, a consistent early-stage investor. Key figures associated with the company include founder Daozhi Liu and Executive Director Gu Shenghan.
JH Cispoly has raised $29.4M across 2 funding rounds.
JH Cispoly has raised $29.4M in total across 2 funding rounds.
JH Cispoly has raised $29.4M in total across 2 funding rounds.
JH Cispoly's investors include Aysar Tayeb.
JH Cispoly has raised $29.4M across 2 funding rounds. Most recently, it raised $14.0M Series B in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 27, 2023 | $14.0M Series B | Aysar Tayeb | |
| Apr 22, 2022 | $15.4M Series A |